Table 4.
Changes of lipid profile levels from the baseline to 6 months duration of GLP-1RA treatment in type 2 diabetes mellitus subjects.
| n | Baseline | Month 6 | Difference at Month 6 | p-Value | ||
|---|---|---|---|---|---|---|
| Baseline vs. 6 Months a | Between Groups, Statins vs. No Statins b | |||||
| Cholesterol(mmol/L) | 0.944 | |||||
| Statin | 52 | 4.04 ± 0.14 | 3.94 ± 0.12 | −0.1 ± 0.13 | 0.441 | |
| No Statin | 7 | 4.49 ± 0.31 | 4.36 ± 0.26 | −0.13 ± 0.19 | 0.515 | |
| TG (mmol/L) | 0.192 | |||||
| Statin | 52 | 1.72 ± 0.11 | 1.73 ± 0.16 | 0 ± 0.13 | 0.972 | |
| No Statin | 7 | 2.19 ± 0.43 | 1.71 ± 0.19 | −0.47 ± 0.31 | 0.177 | |
| HDL (mmol/L) | 0.828 | |||||
| Statin | 19 | 1.22 ± 0.08 | 1.49 ± 0.37 | 0.28 ± 0.38 | 0.479 | |
| No Statin | 3 | 1.03 ± 0.17 | 1.09 ± 0.18 | 0.06 ± 0.07 | 0.501 | |
| LDL (mmol/L) | 0.665 | |||||
| Statin | 44 | 2.6 ± 0.16 | 2.45 ± 0.15 | −0.15 ± 0.15 | 0.322 | |
| No Statin | 4 | 2.63 ± 0.34 | 2.7 ± 0.51 | 0.07 ± 0.25 | 0.794 | |
| VLDL (mg/dL) | 0.192 | |||||
| Statin | 52 | 30.54 ± 1.93 | 30.62 ± 2.83 | 0.08 ± 2.22 | 0.972 | |
| No Statin | 7 | 38.72 ± 7.62 | 30.37 ± 3.36 | −8.35 ± 5.46 | 0.177 | |
TG: triglyceride, HDL, high-density lipoprotein, LDL: low-density lipoprotein, VLDL: very low-density lipoprotein, a paired test, b independent t-test.